Clinical Trial

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.
Protocol Amendment History 4 changes
notable Enrollment increased: 140 -> 240 participants 2026-08-13
minor Trial arms changed: 7 -> 12 2026-08-13
notable Primary completion pushed: 2026-07-01 -> 2026-12-17 2026-07-02
minor Completion pushed: 2026-07-01 -> 2026-12-17 2026-07-02
Trial Details
NCT Number NCT07226817
Lead Sponsor Bristol-Myers Squibb
Conditions Healthy Volunteers
Enrollment 240 participants
Start Date 2025-11-12
Primary Completion 2026-12-17 (estimated)
Study Completion 2026-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-12